David Einhorn Gain Therapeutics, Inc. Transaction History
Greenlight Capital Inc
- $1.97 Billion
- Q4 2023
A detailed history of David Einhorn (Greenlight Capital Inc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Greenlight Capital Inc holds 588,410 shares of GANX stock, worth $988,528. This represents 0.1% of its overall portfolio holdings.
Number of Shares
588,410
Previous 546,560
7.66%
Holding current value
$988,528
Previous $2.45 Million
21.41%
% of portfolio
0.1%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.52MCall Options Held
8.4KPut Options Held
8.7K-
Dme Capital Management, LP New York, NY566KShares$951,0980.05% of portfolio
-
Jones Financial Companies Lllp428KShares$718,5360.0% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$474,1140.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$428,3830.0% of portfolio
-
Marshall Wace, LLP London, X0196KShares$329,3230.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $20M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...